MX2011011511A - Sal de abt-263 y fomas en estado solido de la misma. - Google Patents
Sal de abt-263 y fomas en estado solido de la misma.Info
- Publication number
- MX2011011511A MX2011011511A MX2011011511A MX2011011511A MX2011011511A MX 2011011511 A MX2011011511 A MX 2011011511A MX 2011011511 A MX2011011511 A MX 2011011511A MX 2011011511 A MX2011011511 A MX 2011011511A MX 2011011511 A MX2011011511 A MX 2011011511A
- Authority
- MX
- Mexico
- Prior art keywords
- abt
- salt
- solid
- state forms
- overexpression
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 abstract 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000002424 anti-apoptotic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 abstract 1
- 229950004847 navitoclax Drugs 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Bis-HCI de ABT-263 y los polimorfos cristalinos del mismo son ingredientes farmacéuticos activos apropiados para composiciones farmacéuticas útiles en el tratamiento de una enfermedad caracterizada por sobre-expresión de una o más proteínas anti-apoptóticas de la familia de BcI-2, por ejemplo cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17427409P | 2009-04-30 | 2009-04-30 | |
PCT/US2010/033072 WO2010127190A1 (en) | 2009-04-30 | 2010-04-30 | Salt of abt-263 and solid-state forms thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011011511A true MX2011011511A (es) | 2011-11-18 |
Family
ID=42288743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011011511A MX2011011511A (es) | 2009-04-30 | 2010-04-30 | Sal de abt-263 y fomas en estado solido de la misma. |
Country Status (17)
Country | Link |
---|---|
US (1) | US8362013B2 (es) |
EP (1) | EP2424849A1 (es) |
JP (1) | JP2012525433A (es) |
KR (1) | KR20120005538A (es) |
CN (1) | CN102414186A (es) |
AR (1) | AR076509A1 (es) |
AU (1) | AU2010242923A1 (es) |
BR (1) | BRPI1014369A2 (es) |
CA (1) | CA2758740A1 (es) |
IL (1) | IL215472A0 (es) |
MX (1) | MX2011011511A (es) |
RU (1) | RU2011148521A (es) |
SG (1) | SG175146A1 (es) |
TW (1) | TW201041882A (es) |
UY (1) | UY32598A (es) |
WO (1) | WO2010127190A1 (es) |
ZA (1) | ZA201107592B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
TWI471321B (zh) * | 2009-06-08 | 2015-02-01 | Abbott Gmbh & Co Kg | Bcl-2族群抑制劑之口服醫藥劑型 |
TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
CN102695702A (zh) | 2009-09-20 | 2012-09-26 | 雅培制药有限公司 | 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物 |
CA2780177A1 (en) * | 2009-12-22 | 2011-06-30 | Abbott Laboratories | Abt-263 capsule |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
CN102584744B (zh) * | 2011-01-06 | 2015-07-01 | 上海药明康德新药开发有限公司 | 4-(4-((2-(4-氯苯基)-5,5-二甲基环己基-1-烯)甲基)哌嗪-1-基)苯甲酸的合成方法 |
PT3027618T (pt) | 2013-07-30 | 2020-10-12 | Kronos Bio Inc | Polimorfo de inibidores de syk |
TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
SG10201805670QA (en) * | 2014-01-28 | 2018-08-30 | Buck Inst Res Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
WO2015157120A1 (en) * | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
NZ726365A (en) | 2014-07-14 | 2018-06-29 | Gilead Sciences Inc | Combinations for treating cancers |
TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
WO2018085069A1 (en) | 2016-11-03 | 2018-05-11 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
CN115028640A (zh) | 2017-08-25 | 2022-09-09 | 吉利德科学公司 | Syk抑制剂的多晶型物 |
KR20210131372A (ko) | 2019-02-22 | 2021-11-02 | 크로노스 바이오, 인코포레이티드 | Syk 억제제로서의 축합된 피라진의 고체 형태 |
CN115279375A (zh) | 2019-11-05 | 2022-11-01 | 艾伯维公司 | 用于以navitoclax治疗骨髓纤维化和mpn相关病症的给药方案 |
US20230157970A1 (en) * | 2021-11-19 | 2023-05-25 | Board Of Regents, The University Of Texas System | Targeted Therapy of Kidney Fibrosis |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US630663A (en) * | 1899-05-01 | 1899-08-08 | Wallace George Cook | Combined hay and stock rack. |
US5665379A (en) * | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
IL111004A (en) * | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
US5536729A (en) * | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
US5759548A (en) * | 1993-11-30 | 1998-06-02 | Lxr Biotechnology Inc. | Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5538737A (en) * | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
MX2007014049A (es) * | 2005-05-12 | 2008-02-11 | Abbott Lab | Activadores de apoptosis. |
CN101346128B (zh) * | 2005-10-25 | 2013-10-02 | 雅培制药有限公司 | 包含低水溶解度药物的配方及其使用方法 |
WO2009073835A1 (en) | 2007-12-06 | 2009-06-11 | Abbott Laboratories | Oral compositions of abt-263 for treating cancer |
CN101220008B (zh) | 2008-01-21 | 2011-04-27 | 中国科学院广州生物医药与健康研究院 | 化合物abt-263的合成方法 |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
US20100278921A1 (en) * | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
US20100297194A1 (en) * | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
RU2012101627A (ru) * | 2009-06-18 | 2013-07-27 | Эбботт Лэборетриз | Стабильная суспензия лекарственного средства в виде наночастиц |
CN102695702A (zh) * | 2009-09-20 | 2012-09-26 | 雅培制药有限公司 | 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物 |
CN101798292A (zh) | 2010-03-29 | 2010-08-11 | 无锡好芳德药业有限公司 | ABT-263衍生的新型Bcl-2蛋白抑制剂的制备 |
-
2010
- 2010-04-29 US US12/770,345 patent/US8362013B2/en not_active Expired - Fee Related
- 2010-04-30 JP JP2012508757A patent/JP2012525433A/ja not_active Withdrawn
- 2010-04-30 BR BRPI1014369A patent/BRPI1014369A2/pt not_active IP Right Cessation
- 2010-04-30 TW TW099113921A patent/TW201041882A/zh unknown
- 2010-04-30 CA CA2758740A patent/CA2758740A1/en not_active Abandoned
- 2010-04-30 WO PCT/US2010/033072 patent/WO2010127190A1/en active Application Filing
- 2010-04-30 AU AU2010242923A patent/AU2010242923A1/en not_active Abandoned
- 2010-04-30 CN CN2010800185934A patent/CN102414186A/zh active Pending
- 2010-04-30 AR ARP100101467A patent/AR076509A1/es not_active Application Discontinuation
- 2010-04-30 RU RU2011148521/04A patent/RU2011148521A/ru unknown
- 2010-04-30 KR KR1020117028610A patent/KR20120005538A/ko not_active Application Discontinuation
- 2010-04-30 SG SG2011073632A patent/SG175146A1/en unknown
- 2010-04-30 UY UY0001032598A patent/UY32598A/es not_active Application Discontinuation
- 2010-04-30 EP EP10717392A patent/EP2424849A1/en not_active Withdrawn
- 2010-04-30 MX MX2011011511A patent/MX2011011511A/es not_active Application Discontinuation
-
2011
- 2011-10-02 IL IL215472A patent/IL215472A0/en unknown
- 2011-10-17 ZA ZA2011/07592A patent/ZA201107592B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2758740A1 (en) | 2010-11-04 |
UY32598A (es) | 2010-12-31 |
IL215472A0 (en) | 2011-12-29 |
BRPI1014369A2 (pt) | 2016-04-05 |
AR076509A1 (es) | 2011-06-15 |
ZA201107592B (en) | 2012-06-27 |
CN102414186A (zh) | 2012-04-11 |
KR20120005538A (ko) | 2012-01-16 |
US20100305125A1 (en) | 2010-12-02 |
EP2424849A1 (en) | 2012-03-07 |
SG175146A1 (en) | 2011-11-28 |
US8362013B2 (en) | 2013-01-29 |
WO2010127190A1 (en) | 2010-11-04 |
RU2011148521A (ru) | 2013-06-10 |
AU2010242923A1 (en) | 2011-11-17 |
TW201041882A (en) | 2010-12-01 |
JP2012525433A (ja) | 2012-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011011511A (es) | Sal de abt-263 y fomas en estado solido de la misma. | |
MX2012003408A (es) | Formas cristalinas de abt-263 y solvatos para uso para tratar enfermedades relacionadas con la proteina bcl-2. | |
EA017091B9 (ru) | Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола | |
PH12015500297A1 (en) | Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease | |
EA201001368A1 (ru) | Гетероциклические производные мочевины и способы их применения-211 | |
MY158932A (en) | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
NZ596047A (en) | Stabilized lipid formulation of apoptosis promoter | |
UA96964C2 (ru) | Соединения полициклической мочевины с антибактериальными свойствами | |
MX2007010072A (es) | Derivados de piperidina antibacterianos. | |
MX2012004148A (es) | Compuestos de dioxido de iminotiadiazina como inhibidores de la enzima de disociacion de la proteina precursora amiloide en el sitio beta, composiciones, y su uso. | |
UA110943C2 (uk) | N-ацилсульфонамідні промотори апоптозу | |
MX2013005851A (es) | Sales y formas cristalinas de un agente inductor de apoptosis. | |
UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
IL211120A (en) | Compound, tetracycline converted at position 7c with fluorine, a pharmaceutical preparation containing it and its use in the preparation of drugs for the treatment of bacteria-caused infection | |
WO2010139979A3 (en) | Processes for preparing crystalline forms of dasatinib | |
IN2012DN02139A (es) | ||
MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
MX2010013310A (es) | Derivados de heterociclil urea para el tratamiento de infecciones bacterianas. | |
WO2012107890A3 (en) | Crystal forms of lurasidone chlorhydrate | |
EP2583969A4 (en) | NEW RHODANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS WITH THE RHODANIN DERIVATIVES AS ACTIVE AGENTS | |
EA201001859A1 (ru) | Гетероциклические производные мочевины и способы их применеия | |
EP2796450A4 (en) | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES | |
MX2012007325A (es) | Capsula de abt-263. | |
NZ596527A (en) | Nitrile derivatives and their pharmaceutical use and compositions | |
MX357352B (es) | Uso de derivados poliaminoisoprenilo en un tratamiento antibiotico o antiseptico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |